Case Study
K Pro Campaigns
Identify novel drug combinations through lab-in-the-loop validation
K Pro
Agentic AI
Autopilot Mode
60%
Patient population expanded from 10% to 60% for combination eligibility
Over 40% of pancreatic cancers carry an oncogenic KRAS G12D mutation. While KRAS inhibitors show promise, their limited durability leaves most patients without an effective option.
What K Pro did
Generated a novel biological hypothesis
New synthetic lethal vulnerability identified in KRAS G12D-driven pancreatic cancer
Predicted a new drug combination to increase efficacy
Combination eligibility widened from ~10% to ~60% of KRAS G12D patients.
Lab-in-the-loop validation
Synergy tested & confirmed in preclinical models (cell lines),
Impact
Improved treatment efficacy
Two oncogenic pathways targeted at once, at lower dose.
Faster hypothesis validation
From expert question to novel discovery including lab validation.
Share to:
